Cost-Minimization of Adalimumab and Infliximab In Patients With Moderate To Severe Ulcerative Colitis Refractory To Conventional Therapy
Abstract
Authors
K Jones R Rivera Hurtado E Ruet L Chaves C Izquierdo B Monroy Cruz JG Gay Molina I Gonzalez Godinez